Phase 2 trial reports long-term follow-up outcomes of frontline ponatinib in chronic myeloid leukemia in chronic phase, highlighting sustained efficacy of third-generation kinase inhibition.
Ponatinib is a third-generation BCR::ABL1 tyrosine kinase inhibitor (TKI) with robust activity in Philadelphia chromosome-positive leukemias. Herein, we report the long-term follow-up of the phase 2 trial of ponatinib in chronic myeloid leukemia in chronic phase.
No takes yet. Share an insight, caveat, or question.
Haddad et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: